Recently, Fosun Pharma announced that it will achieve operating income of RMB 41.662 billion in 2025, a year-on-year increase of 1.45%, and net profit attributable to parent companies of RMB 3.371 billion, a year-on-year increase of 21.69%. Among them, revenue from innovative drugs was 9.893 billion yuan, accounting for 33.16% of pharmaceutical business revenue, becoming the core engine of performance growth. The total investment in R&D for the year totaled 5.913 billion yuan, a year-on-year increase of 6.46%. Among them, the R&D investment related to innovative drugs reached 4.303 billion yuan, a year-on-year increase of 15.98%, accounting for 80.26% of the R&D investment in the pharmaceutical business.
During the reporting period, the company's 7 innovative drugs with a total of 16 indications were approved for marketing at home and abroad, 6 innovative drug product marketing applications were accepted, nearly 40 innovative drug clinical trials were approved by China, the United States and Europe, and multiple core products entered key clinical stages, laying a solid pipeline foundation for subsequent commercial growth. In addition, 5 innovative drugs have been newly included in the national medical insurance catalog in 2025, and the CAR-T product Yikaida (Akilenza Injection) has been included in the first version of the commercially insured innovative drug catalog, which will not only improve the patient accessibility of innovative drugs, but also further open up space for commercialization.
The financial report mentioned that Fosun Pharma’s total down payment for external licenses throughout the year exceeded US$260 million, and the total potential milestone amount exceeded US$3.8 billion. Among them, the GLP-1 target YP05002 global licensing project has a down payment of US$150 million and a potential total amount of US$2.085 billion, which fully confirms the company's global competitiveness in innovative research and development. In terms of cooperative development, Fosun Pharma and Teva jointly developed FXB0871; it established source innovation cooperation with a fund under Aditum Bio. At the same time, Fosun Pharma has efficiently introduced a number of overseas original research drugs such as Oconze, Preni, and Daxifei through licensing and achieved approval for marketing in China.
(Fosun Pharma Announcement)
